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A B S T R A C T
Traditional coronary drug-eluting stents (DES) are made from metal and are coated with a permanent polymer
film containing an anti-proliferative drug. Subsequent to stent deployment in a diseased coronary artery, the
drug releases into the artery wall and helps prevent restenosis by inhibiting the proliferation of smooth muscle
cells. Although this technology has proven to be remarkably successful, there are ongoing concerns that the
presence of a polymer in the artery can lead to deleterious medical complications, such as late stent thrombosis.
Polymer-free DES may help overcome such shortcomings. However, the absence of a rate-controlling polymer
layer makes optimisation of the drug release profile a particular challenge. The use of microporous stent surfaces
to modulate the drug release rate is an approach that has recently shown particularly promising clinical results.
In this study, we develop a mathematical model to describe drug release from such stents. In particular, we
develop a mathematical model to describe drug release from microporous surfaces. The model predicts a two-
stage release profile, with a relatively rapid initial release of most of the drug, followed by a slower release of the
remaining drug. In the model, the slow release phase is accounted for by an adsorption/desorption mechanism
close to the stent surface. The theoretical predictions are compared with experimental release data obtained in
our laboratory, and good agreement is found. The valuable insights provided by our model will serve as a useful
guide for designing the enhanced polymer-free stents of the future.
1. Introduction
1.1. Background
Coronary Heart Disease (CHD) remains the leading cause of death
globally, being responsible for around 16% of all deaths annually in high-
income countries (WHO, 2014). Although medical treatments can be used
to manage the symptoms in the early stages of the disease, more advanced
cases ultimately require revascularisation of the affected vasculature to
reduce the risk of myocardial infarction and heart failure. Despite the fact
that coronary artery bypass graft revascularisation procedures are still
commonly performed, with some evidence of better long-term outcomes
for patients with multi-vessel disease and/or existing co-morbidities (Mohr
et al., 2013; Park et al., 2015), the majority of coronary revascularisations
are now performed by percutaneous coronary intervention (PCI).
In PCI, a balloon-mounted stent is expanded into the artery wall to
restore blood flow through the affected lesion (Topol and Teirstein,
2015). Following withdrawal of the balloon, the stent provides per-
manent mechanical support to the vessel wall. Although the use of bare
metal stents (BMS) represented a significant improvement on balloon
angioplasty alone, BMS suffered from relatively high rates of in-stent
restenosis (ISR) (Mehran et al., 1999) due, at least in part, to excessive
smooth muscle cell (SMC) proliferation within the vascular wall (Marx
et al., 2011). It was found that local release of anti-proliferative drugs
from the stent surface could inhibit this proliferative response, with the
first two drug-eluting stents (DES) (Pache et al., 2005; Stone et al.,
2005) achieving quite dramatic reductions in ISR. However, these early
generation devices were also associated with late-stent thrombosis
(McFadden et al., 2004; Joner et al., 2006; Virmani et al., 2004).
Although the precise causes of late-stent thrombosis remain to be de-
termined, discontinuation of dual anti-platelet therapy has been asso-
ciated with its occurrence, indicating incomplete restoration of a
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functional endothelium (McFadden et al., 2004). Further evidence in
support of this came from post-mortem and angiographic investigations
that demonstrated that complete recovery of the endothelium was
much more rapidly achieved in those patients who had been treated
with a bare metal stent, compared to a first generation DES (Joner et al.,
2006; Kotani et al., 2006). Such findings provided the stimulus for the
development of alternative DES, making use of alternative drugs and
coating technologies (Iqbal et al., 2013). There has since been a trend
towards the use of analogues of rapamycin, with the latest devices in-
creasingly using either biodegradable or polymer-free drug coatings to
provide sustained release of the drug.
Stents featuring biodegradable polymer coatings (Abizaid and
Costa, 2010; Guo et al., 2009) include the Biomatrix Stent (Biosensors
International), the DESyne BD NOVOLIMUS Stent (Elixir Medical Cor-
poration), the Nobori Stent (Terumo), the COMBO Dual Therapy Stent
(OrbusNeich), and the Supralimus-Core Stent (SMT). In recent years,
companies have also been pursuing the development of fully bior-
esorbable stents (Huang et al., 2014; Byrne and Kastrati, 2015), ex-
amples of these being provided by the Absorb Stent (Abbott Vascular)
and the DESolve Stent (Elixir Medical Corporation).
Polymer-free stents abandon the use of a polymeric drug carrier
altogether and instead employ technologies that are usually (though not
always) based on directly covering a bare surface of the stent strut with
drug (Khan et al., 2013; Chen et al., 2015). This surface may be rela-
tively smooth, as in the case of the Amazonia Pax Stent (MINVASYS), or
may be specially modified to receive the drug and modulate its sub-
sequent release rate. In the latter case, microporous surface technology
is the most commonly used in the manufacture of currently available
polymer-free stents. A microporous surface contains pits whose
breadth, depth and separation are on the order of micrometres in scale,
and the Yukon (Translumina therapeutics, 2016), Yinyi (Yinyi Biotech,
2016), Vestasync (MIV Therapeutics) and Biofreedom (Biosensors In-
ternational) stents are all examples of devices that employ this tech-
nology. Some nanoporous systems for drug delivery from stents have
also been investigated (Kang et al., 2007; Tsujino et al., 2007).
The mathematical modelling of drug delivery in general (Siepmann
and Siepmann, 2008; Peppas and Narasimhan, 2014), and drug delivery
in the context of DES in particular (Tzafriri et al., 2012; O’Brien et al.,
2013; McGinty, 2014), has received considerable attention in the lit-
erature in recent decades. Mathematical modelling provides a poten-
tially powerful tool in the analysis and design of drug delivery systems.
Such models can help optimise the design of a particular drug delivery
system by guiding what device geometry, composition and drug-
loading should be selected to achieve a desired release profile. This in
turn can lead to a reduction in the number of experiments required for
product development, with consequent savings in time and expense.
More fundamentally, it is sometimes not even clear what the dominant
drug delivery mechanisms in a particular system are, and mathematical
modelling in conjunction with experimental data can assist in identi-
fying these.
To our knowledge, there are no existing modelling studies that focus
on drug release from microporous stent surfaces. However, there does
exist some limited modelling studies on nanoporous surfaces that are of
relevance. Gultepe et al. (2010) developed a model to describe drug
release from a nanotubular metallic surface. Although they characterised
their systems as being nanotubular, they did consider drug-filled tubes
that had diameters as large as 0.2 μm. They assumed that the drug re-
lease was due to a desorption process in which the drug molecules have
to overcome an activation energy barrier before leaving the surface. The
activation energy was assumed to depend quadratically on the surface
coverage of drug, and the resulting model produced results that matched
their experimental data. In a more recent study, Tzur-Balter et al. (2013)
developed a diffusion-based mathematical model to describe drug release
from an eroding porous silicon surface. However, the pore diameters
considered in their study were significantly smaller than a micrometre.
Finally, our group have recently reported on the development of math-
ematical models for nanoporous, nanotubular and smooth surface sys-
tems (McGinty et al., 2015). In the current study, we develop mathe-
matical models to describe drug release from microporous surfaces. In
McGinty et al. (2015), we consider drug diffusion through nanoporous
and nanotubular systems, and these are bulk phenomena that require the
consideration of material porosities. However, in the current study, we
model drug release from a microporous surface, and the novel features of
the behaviour here are surface-dominated. The emphasis here will be on
DES, although our results may also be applicable more generally to any
drug delivery device that employs microporous technology to modulate
the drug release rate.
1.2. Outline
In this paper, we provide a model to describe the elution of drug
from microporous DES. We start by describing the typical drug release
experiment that we wish to model. We then formulate a system of one-
dimensional coupled reaction-diffusion equations describing the drug
release and demonstrate that these reduce to a single diffusion equation
with a spatially varying diffusion coefficient, after making some rea-
sonable assumptions. The release of drug is in two parts: a fast release
phase for the bulk of the drug followed by a slow release phase for drug
located close to the surface. Starting with the assumption of an un-
stirred release medium and no medium replacement at measurements,
we are able to derive an analytical solution for the first phase of release.
Subsequent release when the surface region has been exposed is solved
for numerically. For the case of an unstirred release medium with
medium replacement at each measurement, we derive an analytical
solution for the release profile for both phases of the release. This so-
lution is compared with our in vitro experimental data of drug release
from the Yukon stent. The model is shown to capture the release profile
well, and moreover we show how it is possible to inversely estimate
unknown parameters in the system. Remarkably we are able to demon-
strate mathematically that if the switchover point between the initial fast
release and slow release phases can be determined from the experimental
release profile, then the first phase of the release is determined solely from
the coordinates of this point. Finally, we provide a mathematical model
for the well-stirred case.
We stress that the models presented here are for drug release in an in
vitro environment: such in vitro testing is an important part of early-
stage DES design since it helps to give an indication of the release
profiles that can be obtained from a prototype stent platform as well as
verifying the repeatability of the drug release profiles.
2. Experimental methods
2.1. Characterisation of stent surface topography
Atomic force microscopy (AFM) (MFP 3D, Asylum Research, CA,
USA) was used to characterise the surface features of three uncoated
stainless steel Yukon Choice 4 (3mm×8mm) stents. A small sample
from each stent, consisting of a limited number of struts, was cut free
from the expanded stent and adhered onto a glass slide. AFM scans were
then performed in intermittent contact mode in air, imaging four
random points on each stent surface. All scans were performed at a
frequency of 1 Hz with scan sizes ranging from 1 to 20 μm.
Representative images obtained are shown in Fig. 1 from which we
observe that the depth, breadth and separation of the surface pits are of
the order of micrometres in scale. Rapamycin coated Yukon stents, on
the other hand, have previously been shown to be markedly smoother
than their bare metal equivalents (Wessely et al., 2005).
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2.2. In vitro drug release experiments
The surface of a Yukon Choice stent (3 mm×16mm) was coated
once using a solution of rapamycin (10mg/ml) in ethanol. The
Translumina dose-adjustable coating machine was used to apply the
coating according to the manufacturer's instructions. The drug coated
stent was placed in a glass vial containing 2ml of release medium
(phosphate buffered saline:ethanol (90:10)). The stent was then re-
moved to a separate glass vial containing fresh release medium at each
of the following time points: 10min, 1, 2, 6 h, 1, 3, 7, 14 and 28 days.
The drug-containing release medium from each time point was stored at
−20 °C prior to further analysis. All experiments were performed in
unstirred release media maintained at 37 °C. The samples collected
were analysed using UV-spectroscopy, with the peak absorbance mea-
sured at a wavelength of 279 nm being used to estimate the rapamycin
release from the stent surface. At the end of the release experiment, the
stent was transferred to a glass vial and stored at −20 °C. In order to
determine if any rapamycin was left on the stent after the 28 day in-
cubation period, it was brought to room temperature and then im-
mersed in 2ml of cold methanol overnight. The rapamycin in the me-
thanol solution was then analysed by UV spectroscopy as previously
described. There was no residual rapamycin detected in the methanol
solution, indicating that complete release of the initial drug mass coated
on to the stent (193 μg) had occurred within the 28 day release period.
3. The mathematical model
3.1. Preamble
In Fig. 2(a), we schematically depict a layer of drug covering a
microporous surface. The surface contains pits whose depth, diameter
and separation are of the order of micrometres in size. The system is
placed in a release medium and the drug dissolves. Throughout this
paper, we shall assume that the drug dissolves from its exposed surface
only and that fluid does not penetrate the drug interior. For systems in
which there is significant fluid ingress into the drug bulk, effects such as
fragmentation may be significant and the analysis presented here may
not then be appropriate. However, it should be noted that the classical
dissolution models do not take account of fragmentation (Siepmann and
Siepmann, 2013; Dokoumetzidis and Macheras, 2006; Costa and Lobo,
2001), although there are some studies that do incorporate the effect
(Mangina et al., 2006).
A typical drug molecule has dimensions on the order of nanometres,
and this is three orders of magnitude smaller than the typical dimen-
sions of the microporous pits. Hence surface roughness on the scale of
micrometres will not in general significantly affect the dissolution be-
haviour of individual drug molecules. However, surface roughness on
submicron scales (see Fig. 2(a)) can have a significant effect – for ex-
ample, on a lengthscale of nanometres, there may be van der Waals
interactions between the drug molecules and the surface. A surface that
is rough on a number of different length scales may have a relatively
large surface area, so that a significant proportion of the drug loaded
may be influenced by short-range surface effects. These effects will be
incorporated into the modelling of the current study.
3.2. The unstirred case
Based on the images of the stent surface obtained (see Fig. 1), we
consider a microporous surface as shown schematically in Fig. 2(a). The
surface is covered with drug and placed in an unstirred release medium.
In Fig. 2(a), we have indicated the location of the mean plane of surface
roughness for the microporous surface. For the purposes of formulating
a useable mathematical model, we replace the microporous surface by
the mean plane. We suppose that the mean plane is located at x=0 and
that uniform solid drug now occupies the region above the plane. At
first sight, this might seem a crude assumption. However, for the
Fig. 1. Atomic force microscopy images of the surface of the Yukon Choice stent. Images are representative of three separate stent surfaces, each imaged at four randomly selected
locations, at a scan size of (a) 5 μm and (b) 20 μm. Left hand panels are 2D orthographic projections with the corresponding 3D image shown on the right hand panels. The depth, breadth
and separation of the surface pits are of the order of micrometres in scale.
T.T.N. Vo et al. International Journal of Pharmaceutics 544 (2018) 392–401
394
scenarios we are envisaging here, it does have justification since the
dissolution of most of the drug in the microporous pits (see Fig. 2(a)) is
unaffected by the surface; recall that the pits have dimensions on the
order of micrometres, whereas the range of influence of the surface is
on the order of nanometres. This aligns well with the observed biphasic
release profile shown in Fig. 5(b).
When the system is placed in a release medium, it dissolves from its
exposed surface, and a moving boundary x= s(t) separates the un-
dissolved drug from the release medium as shown in Fig. 2(b). The
surface region is defined to be the neighbourhood of x=0 where ad-
sorption to and desorption from the surface are non-negligible effects,
and we take this to occupy 0< x< a. Fig. 2(b) depicts the system at a
stage when the drug still covers the surface region, so that surface ef-
fects do not enter. However, once the surface region has been exposed,
adsorption/desorption become significant effects (Fig. 2(c)).
We shall develop a mathematical model that tracks the evolution of
two distinct species of drug: free drug dissolved in the release medium
and bound drug adhering to the rough surface. We denote by b(x, t) and
c(x, t) the concentrations of bound drug and free drug, respectively, at
location x and time t. The concentrations for b and c can only change in
the region x> s(t), and so we need only display equations for this
region. Since the release medium is taken to be unstirred here, diffusion
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and where D k,w a and kd are constants. Here Dw is the diffusion coef-
ficient for the free drug, and ka and kd are parameters characterising the
rate of drug adsorption and desorption, respectively. The forms chosen
for ka(x) and kd(x) in (3) ensure that drug adsorption and desorption are
restricted to the surface region only. It should be emphasised here that
b(x, t)= 0 for all x> a, t>0.
It is noteworthy in (1) and (2) that we have not taken the adsorption
rate ka(x)c to be dependent on the concentration of binding sites. This
assumption is valid when the concentration of available binding sites
greatly exceeds the concentration of adsorbate molecules so that the
concentration of binding sites may be taken to be constant. However,
models have previously been proposed that do track the concentration
of binding sites; see, for example, the Langmuir model (Attard and
Barnes, 1998) for the adsorption of gaseous molecules to a solid surface.
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an equation describing the evolution of the total drug concentration.
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For s(t)< x< a, we have
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We assume here that the adsorption/desorption processes equilibriate
on a time scale that is short compared to the other time scales arising in
the system, so that (6) can be replaced by
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Eq. (10) is an appealing result since it implies that the effect of the
rough surface on the drug release rate may be incorporated in a posi-
tion-dependent drug diffusion coefficient. Away from the surface, dif-
fusion is ‘fast’ with =D x D( ) w, but in the neighbourhood of the surface,
diffusion is ‘slow’ with = <D x D D( ) e w.
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Fig. 2. (a) A microporous surface is covered with solid drug. The surface contains pits
whose depth, diameter and separation are on the order of micrometres in size. The mean
plane of the surface roughness is indicated on the figure. The blow-up shows that the
surface is also rough on a submicron scale, and the surface region indicated refers to the
narrow region close to the surface where the effects of adsorption and desorption can be
significant. (b) To make the problem mathematically tractable, we replace the micro-
porous rough surface by the mean plane. However, we do include a surface region in the
modelling where adsorption to and desorption from the surface can be important effects.
The system is placed in a release medium, and the solid drug begins to dissolve. A moving
boundary x= s(t) separates the undissolved drug from the release medium. In the system
as depicted, the surface region is not yet exposed so that adsorption/desorption cannot
occur. (c) At this stage of the release, the surface region is exposed, and adsorption/
desorption become significant effects.
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appropriate to the case of an unstirred release medium. We denote by cs
the solubility of the free drug in the release medium. The solubility is
the maximum possible concentration of dissolved drug in the release
medium, and at the interface between the undissolved drug and the
medium, we suppose that c is at solubility, so that
= = >c c x s t ton ( ), 0.s (12)
Sufficiently far into the release medium, the concentration of drug falls
to zero, so that
→ → ∞ >c x t0 as , 0. (13)
Notice that we have taken the release medium to be infinite in extent
here. This is a reasonable assumption if the release medium has a re-
presentative lengthscale on the order of centimetres, which is the case
for the experiments conducted for the current study. We suppose that at
t=0, the drug layer occupies 0< x< Ld and that the initial con-
centration of undissolved drug is c0. We then have the following initial
conditions:
= = = = >
= = < <
s t L c x t x L
c x t c x L
( 0) , ( , 0) 0 for ,
( , 0) for 0 .
d d
d0 (14)
To obtain a well-posed problem, we need another boundary condition
to determine the motion of x= s(t), the moving dissolution front. This
will be derived by invoking conservation of drug. For s(t)> a, the total
amount of drug in the system is given by
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A similar calculation for s(t)< a gives that
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Combining (15) and (16) now yields
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Combining the equations formulated above now provides the following
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We shall discuss solutions to this problem in Section 4.
3.3. A well-stirred release medium
The formulation for the well-stirred case is very different from that
for the unstirred case. When the medium is well-stirred, a boundary
layer of poorly stirred fluid forms close to the surface of the dissolving
drug layer (Siepmann and Siepmann, 2013; Levich, 1962). This layer is
taken here to be of thickness h; the size of h depends on the degree of
agitation in the fluid bulk. We shall take the release medium to be finite
in extent and to initially occupy < < +L x L Ld w d where Ld and Lw give
the initial thicknesses of the drug and release medium, respectively. A
moving boundary x= s(t), initially located at x= Ld, separates the re-
lease medium from the pure drug layer. We assume here that
≪ ≪h L Ld w and denote by cu(t) the spatially uniform drug con-
centration in the well-stirred medium at time t. In Fig. 3, we schema-
tically depict the various regions and associated drug concentrations.
We assume here that the flux of drug from the surface of the dissol-
ving drug layer is proportional to the difference between the con-
centration of drug in the release medium and the concentration of drug
at the surface. Denoting by j|x=s(t) the flux of drug from x= s(t), we write
= − −=j D s t
c t c
h
( ( )) ( ( ) )x s t
u s
( ) (19)
where cs is the drug concentration on x= s(t), and D(s) is the position
dependent diffusivity of the drug in the release medium as defined by
(11). Eq. (19) can be regarded as a statement of Fick's first law of dif-
fusion at x= s(t). In view of (17), the appropriate equation for the speed
of the front is now
− − = − >D s c t c
h
c c t( ) ( ( ) ) ds
dt
( ) for 0.u s s 0 (20)
Equating the amount of drug that has dissolved with the amount in the
release medium and using the assumptions that ≪ ≪h L Ld w and
cu(t)≪ c0, we have
− ≈L s t c L c t( ( )) ( ).d w u0 (21)
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We shall discuss the solution to this problem in Section 4.
3.4. Release profiles
We begin by considering the unstirred case. For the purposes of the
current study, we define the total amount of drug released by the system
at any time t to be the total amount of drug in solution in the release
medium at this time. Denoting this quantity by M(t), we have that



























Fig. 3. In the case of a well-stirred release medium, a narrow boundary layer of poorly
stirred fluid forms near the surface of the solid drug. The location of the pure drug surface
is denoted by x= s(t), and the system is depicted here at some time t>0. It is assumed
that the flux of drug from the dissolving surface is proportional to the difference between
the drug concentration at the surface and the drug concentration in the well-stirred re-
lease medium. This schematic is not drawn to scale.
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where, recall, A is the cross-sectional area of the drug-covered plane. If









































and if we now employ the second boundary condition in the second line
of the equation list (18), we arrive at





A similar calculation shows that (23) also holds for 0< s(t)< a. In-
tegrating (23) subject to M(0)= 0, s(0)= Ld gives
= −M t L s t( ) Ac ( ( )).d0
All of the drug has dissolved by time t= td where td is determined from
s(td)= 0, and at this time, M(td)=Ac0Ld. Assuming that the boundary
x=0 is impermeable to drug, it is easily shown that dM(t)/dt=0 for
t> td, so that = ∞ =M t M Ac L( ) ( )d d0 . A release profile is a plot of the
fraction of the total drug that has released as a function of time t, and it
















A similar analysis shows that the formula for the release profile for the
well-stirred case is also given by (24).
4. Results and discussion
4.1. The unstirred problem
We now consider the solution to the problem (18). For s(t)> a, the
problem can be solved explicitly, and the details of the solution method
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This solution remains valid until t= ta where s(ta)= a, so that
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where θ is determined from (26). This problem cannot be solved ana-
lytically, and so we employed a front-tracking numerical scheme to
obtain approximate solutions. The details of the scheme can be found in
Appendix A. The transition between the rapid and the slow release can
be identified on the release profile shown in Fig. 5(a) and occurs at the
point
∞ = − −t M t M L a θ a L( , ( )/ ( )) (( ) / , 1 / ).a a d d2 2 (28)
Eq. (28) is of value when assessing experimental data. If in an experi-
mental release profile the transition point is clearly identifiable, then
comparing the experimental result with the theoretical prediction (28)
should enable the estimation of the parameters a and θ if Ld is known.


















Eq. (26) can now be used to provide an estimate for the free drug dif-
fusion coefficient Dw if cs/c0 is known. Conversely, if Dw is known, (26)
provides an estimate for cs/c0, which in turn can provide an estimate for
the drug solubility cs if c0 is known.
Remarkably, it transpires that the first phase of the release profile is
determined solely from the coordinates of this transition point. To see
this, we combine (24) and (25) to obtain
∞
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d d
a


















The significance of this last result is that, if we can identify the tran-
sition point on the experimental release profile, then this is all the in-
formation we need to simulate the first phase of the release.
4.1.1. Numerical solutions
In Fig. 4, we display theoretically generated drug release profiles for
the unstirred case where the release medium is not replaced. The curves
were calculated using the formulae (24) and (25) and by numerically
integrating (27) . The results illustrate the quite wide variety of release
behaviours the system is capable of exhibiting. Fig. 4(a) shows the ef-
fect of varying the effective drug diffusion coefficient De in the surface
region, and the results are as expected with the release rate in the slow
phase decreasing with decreasing De. The effective diffusion coefficient
depends on the adsorption/desorption properties of the drug molecules
with the surface.
The effect of varying the drug solubility cs is shown in Fig. 4(b). The
behaviour here is seen to be strongly dependent on the solubility in the
early rapid stage of the release (see the inset), with the curves ex-
hibiting a quite dramatic slowing in the drug release rate with de-
creasing cs. This behaviour can be understood by noting that for
cs/c0≪ 1, we have from (26) that ≈θ D π c c2 / /w s 0, so that














implying that the duration of the rapid release phase depends on the
square of the inverse of the drug solubility. This remark is consistent
with the behaviour exhibited in the inset of Fig. 4(b).
In Fig. 4(c), we display release curves for various thicknesses of the
surface region. For these curves, the initial stages of the profiles are
identical because the surface plays no role in the release behaviour
here. In designing a real system, changing a would correspond to
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changing the roughness characteristics of the surface. However, it
should be stated that in the current study, no explicit connection has
been made between the parameters appearing in the mathematical
model and surface roughness parameters (Whitehouse, 2002).
Nevertheless, we can conclude that from the point of view of delaying
the release of a larger fraction of the drug, roughness on both micron
and submicron scales is preferable to roughness on submicron scales
alone since the total surface area in the former case is larger. Larger
surface areas imply that a larger fraction of the drug load is initially
adhering to the surface, and this fraction releases more slowly. In terms
of our modelling, larger surface areas correspond to larger values of the
effective surface thickness parameter a.
4.1.2. Implications for choice of drug to be coated on microporous stents
Whilst biphasic kinetics are clearly a feature of these microporous
stents, it is evident from Fig. 4 that the majority of the drug is released
rapidly. Indeed, for the wide range of parameters that we have simu-
lated, most of the drug is released within the first day. In order to
evaluate the potential clinical significance of this finding, we must as-
sess these rapid release profiles in the context of restenosis develop-
ment, a process that occurs over a period of weeks after stent im-
plantation.
We note that the drugs coated on early DES included heparin, pa-
clitaxel and rapamycin. Early mathematical modelling (for example
Hwang et al., 2001) helped explain the failure of hydrophilic heparin
stents and the relative success of paclitaxel and rapamycin eluting
stents, based on analysis of their partitioning and transport properties
in arterial tissue. In particular, rapamycin and paclitaxel are extremely
poorly soluble hydrophobic compounds that bind tenaciously to the
arterial wall. Rapamycin is an anti-proliferative compound that targets
the FK-binding protein 12 (FKBP12) (Daemen and Serruys, 2007). This
complex subsequently binds to the mammalian target of rapamycin
(mTOR) and thereby interrupts the cell cycle in the G1-S phase. Pacli-
taxel is also an anti-proliferative compound; however, it inhibits
neointimal growth by binding with and stabilising microtubules, re-
sulting in cell-cycle arrest in the G0–G1 and G2-M phases (Martin and
Boyle, 2011).
Recently, mathematical modelling has been used to help explain
how differences in the binding properties of rapamycin and paclitaxel
lead to different drug persistence times in the wall, suggesting that the
optimal delivery strategy is drug dependent (Bozsak et al., 2014). For
example, whilst the timescale for binding of rapamycin (∼5min) is
much quicker than for paclitaxel (∼5 h), the timescale for unbinding
of rapamycin (∼11 h) is considerably shorter than that of paclitaxel
(∼210 h). Based on time scale analysis, Bozsak et al. (2014) postu-
lated that paclitaxel-eluting stents perform optimally by releasing
their drug either very rapidly (within a few hours) or very slowly
(over periods of several months) (Bozsak et al., 2014), and in contrast,
rapamycin-eluting stents perform optimally only when drug release is
slow (Bozsak et al., 2014). The implication is that for the Yukon
Choice stent studied here, coating with paclitaxel or a drug with si-
milar binding properties may actually be preferable in terms of
combating restenosis. Alternatively, strategies to slow the rapamycin
release may be advantageous, and we note that the manufacturer of
the stent under study is actively pursuing such approaches. Since the
current state-of-the-art indicates that receptor saturation is strongly
linked with efficacy (Tzafriri et al., 2012), we further note that it may,
in principle, be possible to design a microporous stent where the rate
of the second phase of release is tuned to match declining receptor
saturation levels, thereby acting to replenish the drug in the tissue and
prolonging receptor saturation.
4.1.3. Unstirred, replaced release medium
The situation we have described above assumes that the release
medium is not changed between measurements. However, it is also
common for the stent to be removed and placed in a fresh release
medium between measurements. This strategy is typically adopted
where there are constraints on the limit of detection of the drug. It is
therefore of interest also to consider the case where the release medium
is replaced. Mathematically this is modelled by a resetting of the drug
Fig. 4. Theoretically generated drug release profiles for the unstirred case without
medium replacement. The curves were calculated using (24) and (25) and by numerically
integrating (27). Here Dw is the diffusion coefficient of the drug in the release medium, De
is the effective diffusion coefficient of the drug in the surface region, Ld is the initial
thickness of the drug layer, a is the thickness of the surface region, c0 is the initial con-
centration of the undissolved dry drug, and cs is the solubility of the drug in the release
medium. Unless stated otherwise on the figure, the parameter values used are
= × −D 5 10w 7 cm2 s−1, = −D D/ 10e w 6, Ld=10 μm, a/Ld=0.2, and c0/cs=50. In the
plots, we display drug release profiles for (a) varying values of the effective drug diffusion
coefficient in the surface region, (b) varying values of the solubility, and (c) varying
thicknesses of the surface region.
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concentration to zero in the release medium at every measurement time
point. Assuming that the transition time ta between the fast release
phase and the slow release phase corresponds to one of the measure-
ment time points, the release profile can be computed using the fol-
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where ti, i=1, …, n− 1 are the experimental time points before the
transition, tn= ta is the time of the transition and td= tn+ a2/θ*2 is the
time by which all of the drug has dissolved. In (32), θ and θ* are both
constant parameters, where θ is determined by solving (26) and θ* is








































Once again, provided that Ld is known, a and θ can be estimated from
the experimental data point ( ∞t M t M, ( )/ ( )a a ). We can again estimate a
using (29), and then
= −
+ − +⋯+ − −
θ L a
t t t t t
.d
n n1 2 1 1 (34)
We can now estimate Dw using (26) if cs/c0 is known or vice-versa.
4.1.4. Comparison with experimental data
In Fig. 5, we display the results of the release experiment described in
Section 2.2. Fig. 5(b) shows the measured drug release profile plotted
against the square root of time. The release profile is clearly biphasic, i.e.
there is a clear transition point separating a fast initial rate of release from
a subsequent slower rate of release. A simple single phase dissolution
model (McGinty et al., 2015) is incapable of replicating such behaviour.
In Fig. 5(a), we compare the theoretical profile (32) with the experi-
mentally measured release profile plotted as a function of time. In order to
use the formula (32), values for the parameters θ/Ld, a/Ld, θ*/Ld and tn= ta
must be selected that are consistent with (34), and values were chosen here
to obtain a good fit with the experimental data. The values selected can be
found in the caption of Fig. 5. It is noteworthy that it is not necessary to
explicitly choose values for D k k c, , ,w a d 0 and cs to implement the fitting.
However, these values will satisfy the constraints (26) and (33) and so may
be deducible indirectly depending on which parameters are known for a
particular system. The reverse question is also worth considering – what
system parameters need to be known in advance in order to apply the model
directly to a particular systemwithout fitting? Inspecting Eqs. (26), (32), (33)
and (34), it is seen that it is sufficient to specify values for D D c c L, , / ,w e s d0
and a to implement the model.
The biphasic character of the release in Fig. 5(a) is clear, with a
relatively rapid initial release of most of the drug, followed by a slower
release of the remaining drug. The theory developed in this paper posits
that the fast release here corresponds to dissolution of drug away from
the surface region, while the slow release corresponds to drug dis-
solution in the surface region. It is clear that our mathematical model is
capturing the experimentally observed release profile well.
4.2. The well-stirred problem
To obtain the solution for the well-stirred case, we must solve the
initial-value problem (22). The solution to (22) for s(t)> a is given by
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This solution remains valid until t= ta where s(ta)= a. Using (35), we
find that






















We remark that this quantity is only defined for
− − >c L a c L1 ( )/ 0d s w0 , or > −c L c L a( )s w d0 . This corresponds to our
intuitive expectations here since if < −c L c L a( )s w d0 , the release
medium would become fully saturated with drug before s(t) could reach
a, and dissolution would then cease.
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for t> ta. The time for all of the drug to dissolve, t= td, is determined
by solving s(td)= 0. Using (38), this gives
Fig. 5. (a) Comparison between experimental drug release data and the theoretical drug release profile (32). The solid curve shown is theoretical, and the parameter values used to
generate it are a/Ld=0.225, θ/Ld=1.475, θ*/Ld=0.078 and ta=0.086 days. The diamonds give the experimental release data, and the inset highlights the release behaviour over the
first day of release. (b) Plot of the experimental release data versus the square root of time.
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Clearly for this to be physically meaningful we require that td> ta,
which implies that − >c L c L/ 0s w d0 or >c L c Ls w d0 . This last condition
implies that in order for td to be defined, the release medium must be
capable of accommodating all of the drug before saturating. Finally for
t> td, we clearly have s(t)= 0.
Combining the results above and using (24), we now have that
5. Conclusions
Microporous drug release systems have surfaces that are rough on
the micron scale; that is, the breadth, depth and separation of the
surface pits have dimensions of the order of microns. However, the
molecular dimensions of drug molecules are typically of the order of
nanometres, three orders of magnitude smaller than the dimensions of
the pits. Hence, for solid drug that dissolves from its surface interface
with the release medium only, the dissolution behaviour of most of the
drug molecules in the pits may not be significantly affected by the
presence of the surface. Hence, the concept that roughness on the scale
of the micron can in and of itself significantly retard the release of a
substantial fraction of the drug may not be valid for some systems.
However, roughness on submicron scales can significantly retard drug
release via surface effects such as Van der Waals interactions; these
forces act over a much shorter range than a micron. Nevertheless, such
forces can still affect a significant amount of drug for systems whose
surfaces are rough on both the micron and submicron scales since the
total surface area can then be large. These observations motivated the
development of the biphasic mathematical model presented in the
current study.
The mathematical model developed here is, to the best of our
knowledge, the first that attempts to model drug release from micro-
porous surfaces. Although our model does incorporate a number of
significant simplifying assumptions to enable analytical progress, it
does successfully capture the key features of the experimentally ob-
served release behaviour. We conducted drug release experiments for a
Yukon stent coated with rapamycin and found that the release profile
had a distinct two-stage character, with most of the drug releasing re-
latively rapidly over a period of about half a day, and the remainder of
the drug releasing more slowly over a period of about a week. This
biphasic character of the experimental release is captured very well by
our theoretical model. In our theoretical formulation, the slow release
phase is accounted for by an effective diffusion coefficient for the drug
in the neighbourhood of the surface that is smaller than the free drug
diffusion coefficient.
Simulations of the mathematical model indicate that microporous
systems are capable of exhibiting quite a broad range of release beha-
viours. Amongst the parameters that may be used to tune the character
of release profiles are the thickness of the drug layer and, of course, the
surface roughness. Moreover, and more interestingly, we note that ex-
perimental release data in conjunction with theoretical profiles can be
used to estimate key system parameters, such as the free drug diffusion
coefficient.
Finally, we believe that it is appropriate to acknowledge that a
number of assumptions have been made in this analysis. Firstly, we
replace the actual microporous surface by a mean plane representation,
with our justification being that the dissolution of most of the drug in
the microporous pits is unaffected by the surface. Secondly, we have
assumed that the drug dissolves from its exposed surface only. Thirdly,
we have not taken the drug absorption rate on the stent surface to be
dependent on the concentration of binding sites, an assumption which
is valid when the concentration of available binding sites greatly
exceeds the concentration of absorbate molecules. In deriving our
analytical solutions, we have assumed that the release medium is in-
finite in extent, which is a reasonable assumption when the length scale
of the release medium is much greater than the diffusion length.
Finally, the mathematical model presented does not account for the
possibility of drug degradation in the release medium. A model which
accounts simultaneously for drug release and degradation of drug is
beyond the scope of this study and calls for the development of more
sophisticated modelling approaches, which we will pursue in future
work.
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